Mastodon

Etadexe-MEZ (Drops) Instructions for Use

Marketing Authorization Holder

Moscow Endocrine Plant FSUE (Russia)

ATC Code

S01XA (Other preparations for the treatment of eye diseases)

Dosage Form

Bottle Rx Icon Etadexe-MEZ Ophthalmic drops 0.5%: tube-dropper 1.3 ml, bottle 5 ml with dropper cap, bottles 5 ml.

Dosage Form, Packaging, and Composition

Ophthalmic drops 0.5% 1 ml
Hydroxyethylaminoadenine hydrobromide 5 mg

Excipients: purified water, dextran 60, sodium methylparaben.

1.3 ml – tube-droppers (2) – cardboard packs.
5 ml – bottles (1) with a dropper cap – cardboard packs.
5 ml – bottles (1) – cardboard packs.

Clinical-Pharmacological Group

A drug that stimulates regeneration processes for topical use in ophthalmology

Pharmacotherapeutic Group

Tissue regeneration stimulant

Pharmacological Action

Etaden-8-(2-hydroxyethyl)-aminoadenine hydrobromide monohydrate.

A purine derivative, a stimulator of reparative cell regeneration. The mechanism of action is associated with the activation of nucleic acid synthesis.

It accelerates reparative processes, primarily in rapidly renewing tissues (epithelial and hematopoietic).

It reduces edema, pain, and increases visual acuity. It promotes the regeneration of corneal defects, the formation of a scar, and the restoration of a smooth spherical surface of the cornea.

Indications

Stimulation of corneal epithelium regeneration in various eye lesions accompanied by a violation of its epithelial integrity: epitheliopathy after infectious and inflammatory diseases; dry eye syndrome (in combination with artificial tear preparations); bullous keratopathy; initial epithelial-endothelial dystrophy; epithelial defects after ophthalmic surgeries (cataract removal, glaucoma surgery); postoperative descemetitis; recurrent erosions; ulcers of bacterial, fungal, and herpetic etiology (as part of combination therapy); burns; keratitis with ulceration and damage to the superficial layers of the cornea.

ICD codes

ICD-10 code Indication
H04.1 Other disorders of lacrimal gland (dry eye syndrome)
H16 Keratitis
H16.0 Corneal ulcer
H16.8 Other forms of keratitis
H18.1 Bullous keratopathy
H18.4 Corneal degeneration
H18.5 Hereditary corneal dystrophies
H18.8 Other specified disorders of cornea
T26 Thermal and chemical burns confined to the eye and its adnexa
ICD-11 code Indication
9A1Z Diseases of the lacrimal system, unspecified
9A70.Z Hereditary corneal dystrophies, unspecified
9A71 Infectious keratitis
9A76 Corneal ulcer
9A78.20 Bullous keratopathy
9A78.4 Corneal degeneration
9A78.Z Other diseases of cornea, unspecified
9A7Z Diseases of the cornea, unspecified
NE00 Burn of eye and adnexa

Dosage Regimen

The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen.

Topically, as instillations into the conjunctival sac – 2-3 drops 3 times/day.

Depending on the etiology of the process and the severity of the organ damage, the local prescription of other specific and symptomatic medications is possible in parallel.

The duration of treatment depends on the course of the disease and should not exceed 10 days.

The absence of a therapeutic effect when using the drug for 10 days indicates the need to use other methods of treatment.

Adverse Reactions

Allergic reactions.

Contraindications

Hypersensitivity.

Special Precautions

Freezing of the solution is not allowed.

Storage Conditions

Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.

Dispensing Status

Rx Only

Important Safety Information

This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.

Medical Disclaimer

TABLE OF CONTENTS